Home » News

ASCO 2012 Multiple Myeloma Update – Day Four: Poster Presentations On Current Myeloma Treatments

No Comment By
Published: Jun 5, 2012 3:50 pm

Today concludes this year’s American Society of Clinical Oncology (ASCO) annual meeting, which began on Friday in Chicago.  However, yesterday was the last day with any multiple myeloma-related sessions.

During yesterday’s poster session, important new research findings were summarized on posters throughout a large conference hall.

The studies were on a wide variety of myeloma-related topics ranging from new treatments being developed for myeloma, to currently used regimens, to secondary cancers, to precursor myeloma diseases, and much more.

This update covers some of the myeloma-related studies presented during the poster session, in particular, ones about treatment regimens that are commonly being used by myeloma patients.

Additional updates will summarize posters from yesterday afternoon that were on other myeloma-related topics.  One of these updates was published yesterday (see related Beacon news).

Long-Term Revlimid-Dexamethasone Results

During the poster session, one poster summarized results from a retrospective study that analyzed long-term outcomes of 286 newly diagnosed myeloma patients who received induction (initial) therapy with Revlimid (lenalidomide) and dexamethasone (Decadron) (abstract).

Overall, 72 percent of patients responded, with 11 percent achieving a complete response, 14 percent a very good partial response, and 46 percent a partial response.

The median time to progression was 30 months.  The median overall survival time was 7.4 years, with an estimated 67 percent being alive at five years.

The researchers also studied the median overall survival times of certain patient subgroups.  The median overall survival time was 6.2 years for patients older than 65 years of age.  The overall survival estimates for patients classified as Stage 1, 2, and 3 by the International Staging System were 82, 65, and 44 months, respectively.

The researchers conclude that the median survival of more than seven years reflects the efficacy of the novel agents, both at diagnosis and at relapse, and confirms the survival improvements seen in multiple myeloma in the last decade.

Revlimid-Velcade-Dexamethasone Induction Therapy

Another poster summarized results from a retrospective study that analyzed outcomes of 148 newly diagnosed myeloma patients who received induction therapy with Revlimid, Velcade (bortezomib), and dexamethasone, known as RVD, and then went on to receive a stem cell transplant (abstract).

The results showed that following RVD therapy and stem cell transplantation 96 percent of patients responded, including 64 percent who achieved a complete response (57 percent achieved a stringent complete response), 22 percent a very good partial response, and 8 percent a partial response.

The median estimated progression-free survival time was 47 months, and median overall survival time was not yet reached.

The researchers additionally stated that RVD was well tolerated.

Stem Cell Transplantation Followed By RVD For High-Risk Myeloma

Another poster summarized results from a retrospective study that analyzed outcomes of 37 newly diagnosed high-risk myeloma patients who underwent induction (initial) therapy and stem cell transplantation followed by RVD maintenance therapy (abstract).

The results showed that 89 percent of patients responded to the treatment regimen, including 60 percent who achieved a complete response, 21 percent a very good partial response, and 8 percent a partial response.

In addition, responses got deeper with each stage of treatment (induction therapy, stem cell transplantation, and maintenance therapy).  For instance, the percentages of patients achieving a stringent complete response from each stage of therapy were 8 percent, 22 percent, and 46 percent, respectively.

The median estimated progression-free and overall survival times were not yet reached.

The researchers additionally stated that no serious side effects were observed and that RVD maintenance was well tolerated.

Second Stem Cell Transplants For Relapsed Myeloma

Another poster summarized results from a retrospective study that analyzed outcomes of 98 myeloma patients who received a second stem cell transplant because their disease relapsed (abstract).

The median time between stem cell transplants was 46 months, and the patients received a median of two lines of therapy between transplants.

Overall, 86 percent of patients responded after the second transplant, with 31 percent achieving a complete response, 20 percent a very good partial response, and 36 percent a partial response.

The median progression-free survival time was 10.3 months, and the median overall survival time was 33 months.  Patients who had high-risk chromosomal abnormalities prior to the second transplant had similar survival times to those without high-risk abnormalities.

However, shorter response to the first transplant, rapidly growing abnormal plasma cells at the time of the second transplant, a higher number of treatment regimens used prior to the second transplant, and not achieving a complete response prior to the second transplant all affected survival times.

The researchers conclude that stem cell transplantation is effective and safe for relapsed myeloma patients.

Additional myeloma-related posters from yesterday, Day 4 of the ASCO 2012 meeting, will be summarized in another ASCO daily update to be published later today.  Additional coverage of key research results from the meeting will continue throughout the rest of the week in individual, topic-specific news articles.

For all Beacon articles related to this year’s ASCO meeting, see The Beacon’s full ASCO 2012 coverage.

Tags: , , , , , , , , , , , ,


Related Articles: